You are here: Published Weight Loss Studies > Drug Treatment Studies > Sibutramine (Meridia)
|
Index of published clinical studies related to Sibutramine (Meridia)
|
Research articles of clinical studies are listed by publication date, starting with the latest. Click on the title to view the abstract.
Well-designed clinical studies related to Sibutramine (Meridia)
Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. [2006 Dec]
Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. [2006 May]
Effects of sibutramine treatment in obese adolescents: a randomized trial. [2006 Jul 18]
Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. [2006 Jun 01]
Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. [2006 May]
Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder. [2006 May]
Influence of weight reduction by sibutramine on female sexual function. [2006 May]
Randomized trial of lifestyle modification and pharmacotherapy for obesity. [2005 Nov 17]
[Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial] [2005 Sep]
[Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents] [2005 Apr]
Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. [2005 Aug]
Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. [2005 Aug]
Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. [2005 Jul-Aug]
Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. [2005 Jul]
Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure. [2005 Jun]
Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. [2005 Jan-Feb]
Two-year outcome of a combination of weight loss therapies for type 2 diabetes. [2005 Jun]
Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. [2005 Feb]
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. [2005 May]
Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. [2005 May]
[Serum leptin and insulin resistance in obesity and effects of sibutramine on them] [2003 Dec]
Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease. [2004 Oct]
Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. [2004 Dec]
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. [2005 Jan]
Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. [2005 Mar]
Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. [2004 Dec]
Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. [2005 Feb]
Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. [2004 Aug]
Bariatric surgery patients' views of their physicians' weight-related attitudes and practices. [2004 Oct]
Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. [2004 Sep]
Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. [2004 May]
Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers. [2004 Aug]
What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. [2004 Aug]
The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. [2004 Jun]
The efficacy and safety of sibutramine for weight loss: a systematic review. [2004 May 10]
Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. [2004 Apr]
Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? [2004 Mar]
Food intake with an antiobesity drug (sibutramine) versus placebo and rorschach data: a crossover within-subjects study. [2004 Apr]
Cost-effectiveness of sibutramine in the treatment of obesity. [2004 Jan-Feb]
Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. [2004 Apr]
Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. [2004 Mar]
Great expectations: "I'm losing 25% of my weight no matter what you say". [2003 Dec]
A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. [2003 Nov]
Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. [2003 Nov]
One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. [2003 Sep]
Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. [2003 Sep]
Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. [2003 Aug]
Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). [2003 Aug]
Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. [2003 Mar-Apr]
Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome. [2003 Jun]
Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. [2003 Apr 09]
A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. [2003 Jan]
Paradoxical effect of sibutramine on autonomic cardiovascular regulation. [2002 Nov 05]
Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. [2002 Sep]
Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study. [2002 May-Jun]
The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. [2002 Apr]
Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. [2002 Feb]
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. [2002 Jan]
Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. [2002 Feb]
Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. [2002 Jan]
Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. [2002 Jan]
[A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects] [2001 Sep]
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. [2001 Nov]
Long-term weight loss with sibutramine: a randomized controlled trial. [2001 Sep 19]
Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. [2001 Sep]
Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. [2001 Jun]
[The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial] [2001 May 21]
[Sibutramine--antidepressive agent tested against obesity] [2001 Apr 11]
Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. [2001 May]
Influence of sibutramine on energy expenditure in African American women. [2001 Apr]
Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. [2001 Apr]
Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. [2000]
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. [2000 Jun]
Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. [2000 Apr]
Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. [2000 Dec 23-30]
Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. [2001 Jan 22]
Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. [2000 Sep]
Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. [2000 Jul 24]
Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. [2000 Jan]
A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. [2000 Feb]
The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. [1999 Oct]
The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. [1999 Oct]
Absence of cardiac valve dysfunction in obese patients treated with sibutramine. [1999 Jul]
Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. [1999 Feb]
Sibutramine produces dose-related weight loss. [1999 Mar]
Thermogenic effects of sibutramine in humans. [1998 Dec]
Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? [1998 Aug]
A comparison of sibutramine and dexfenfluramine in the treatment of obesity. [1998 Jul]
Effects of sibutramine on resting metabolic rate and weight loss in overweight women. [1998 Mar]
Sibutramine reduces food intake in non-dieting women with obesity. [1998 Jan]
Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. [1998 Jan]
A double-blind randomized placebo-controlled trial of sibutramine. [1996 May]
Elevated serum liver enzymes in obesity: a dilemma during clinical trials. [1991 Dec]
Other clinical studies related to Sibutramine (Meridia)
Medical management of obesity. [2006 Sep-Oct]
[Pharmacotherapy of obesity] [2006 Dec]
Drug treatments for obesity: orlistat, sibutramine, and rimonabant. [2007 Jan 06]
Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? [2006 Nov]
New findings from the Bipolar Collaborative Network: clinical implications for therapeutics. [2006 Dec]
Pharmacotherapy of obesity. [2006 Oct]
Baseline serum folate level may be a predictive factor of weight loss in a morbid-obesity-management programme. [2006 Nov]
|
